A Medical Device Daily

BioNanomatrix (Philadelphia), a company developing nanoscale whole genome imaging and analytic platforms, and Complete Genomics (CGI; Mountain View, California), a genome sequencing company, said they have formed a joint venture that has received an $8.8 million grant award from the U.S. National Institute of Standards and Technology Advanced Technology Program (NIST-ATP) to develop a system capable of sequencing the entire human genome in eight hours at a cost of less than $100.

“We and our colleagues at CGI are thrilled that NIST-ATP sees the potential of our combined technologies to achieve this ambitious goal,” said Dr. Michael Boyce-Jacino, president/CEO of BioNanomatrix. “Our joint venture team will pool our innovative technologies — Complete Genomics’ novel sequencing chemistry and our advanced nanofluidic platform — to develop a breakthrough technology that will radically decrease the cost and time required for sequencing the genome, making it possible for the first time for genetic information to be incorporated into routine medical care.”

According to BioNanomatrix and CGI, the current cost of sequencing the roughly three billion base pairs in the human genome is more than $100,000. If successful, the $100 genome project could transform the role of genomics in medicine, making whole genome sequencing feasible for routine use in medical care and delivering more diagnostic and predictive information than the genetic tests available today, the companies said.

“We tried to approach this project from the perspective of the clinician, looking at the requirements and opportunities associated with incorporating genetics into routine clinical diagnostics,” said Dr. Radoje (Rade) Drmanac, chief science officer and co-founder of Complete Genomics.

“Accuracy, speed and low cost were paramount considerations. While there are a number of powerful and elegant sequencing strategies available or under development, we determined that we needed a completely novel approach to overcome their inherent limitations and achieve our $100 cost objective. We are optimistic that the combination of our two highly innovative approaches has a good chance of success.”

The joint venture has proposed adapting a DNA sequencing chemistry combined with linearized nanoscale DNA imaging to create a system that can “read” very long DNA sequences of greater than 100,000 bases at high speed and with accuracy exceeding the current industry standard. By condensing a wide range of genetic tests into a single, cost-effective platform, the proposed technology has the potential to enable improvements in the diagnosis and personalized treatment of a wide variety of health conditions, as well as the ability to deliver individually tailored preventive medicine, the companies said. The $100 genome would also have applications in medical research and drug development.

The NIST-ATP award is a matching grant for the five years of the project. The total project cost is expected to be about $17.8 million, including both the grant award from NIST-ATP and the matching funds that will be provided by the joint venture partners.

BioNanomatrix is developing nanoscale whole genome imaging and analytic platforms for applications in clinical genetics, cancer diagnostics and other biomedical applications. The company was founded as a spin-out of Princeton University in 2003.

Complete Genomics has developed a combination of high-density DNA nanoarrays, sequencing-by-hybridization and combinatorial probe-ligation chemistry, and high-performance computing techniques intended to provide researchers and clinicians with fast, accurate, and inexpensive complete human genome sequencing.